5
問題一覧
1
Active Ingredient, Diluent or Filler, Binder, Disintegrant, Lubricant
2
Oral Solution
3
Oral pharmaceutical solutions are usually formulated so that the patient receives the usual dose in a conveniently administered volume, such as 5 mL (1 tsp), 10 mL, or 15 mL (1 tbsp).
4
Enhances crystal growth formation
5
Suspended particles settle rapidly
6
Formation of a compact when the particles eventually settle
7
Suspensions are chemically more stable than solutions.
8
Add an amount of flocculating agent that will bring about a sedimentation volume equal to 1
9
Human insulin
10
Gelatin coated tablet
11
Class III
12
Sun protection factor
13
Betaine
14
Tablet Binder
15
Adsorbent
16
Humectant
17
Emulsion and suspension
18
Castor Oil
19
Yellow wax, yellow petrolatum
20
I, III
21
I, II, IV
22
6.21 mL
23
Liniments – Oleaginous
24
I, II, III
25
Purified Water
26
Remains stable in rectal fluids
27
It is a naturally occurring alkaloid.
28
Lip Balms, Mouthwashes, Antiperspirants, Diaper Ointments
29
Strong Antimicrobial
30
HMW alcohols
31
Tumbling
32
Reversible protein precipitation
33
Gas Sterilization
34
Nitroso-Dyes
35
Decrease dissolution leading to a less violent effervescence.
36
Chipping
37
I, II and III
38
Magaldrate
39
II-V-III-I-IV
40
Coat the capsules with polyvinyl acetate phthalate.
41
Aging
42
100 – 120 mEq
43
Granules will be hard
44
Antioxidant
45
Type II
46
Brownian motion
47
225 g
48
Chewable tablet
49
Refractive index
50
Physiological
51
Ion-Dipole, Ion- Induced Dipole Forces
52
5- to 6-membered rings
53
Gibbs Free Energy
54
Metal Complexes, Organic Complexes, Inclusion/Occlusion Compounds
55
Hexadentate
56
∆ E = EB + EA
57
3rd Law of Thermodynamics
58
I, II, III
59
I, II, III
60
I, III, IV
61
I, II, III
62
Cup and Bob, Cone and Plate
63
Tobramycin, Chloramphenicol Palmitate Suspension
64
Electrokinetic Potential
65
0.76 g
66
0.5
67
Hydrogen bond
68
Micelles are aggregates of molecules or ions of the substance dissolved in the dispersion medium.
69
Light Scattering
70
The configuration of a solid molecule has NO effect on its solubility.
71
The solubility of a solid in an ideal solution depends on the temperature, melting point of the solid and molar heat of fusion.
72
Gelatin
73
Work Of Adhesion
74
AOTA
75
both Nernst Potential and Electrothermodynamic Potential
76
The velocity of the particles decreases with decreasing particle size
77
Spherocolloids form dispersions of relatively high viscosity
78
9%
79
18 mL
80
– 1.6 dynes/cm
81
NOTA
82
When the ligand provides one group for attachment to the central ion, the chelate is called bidentate
83
NOTA
84
NOTA
85
NOTA
86
50%
87
1.9
88
Dispensing the remaining balance of medicines ordered in the prescription
89
Only the brand name is written on the prescription, with the phrase, “No substitution”
90
PDEA
91
Philippine Pharmacy Act
92
Primary care, medicines, diagnostic and laboratory tests, preventive, curative, rehabilitative services
93
S-1
94
NOTA
95
RA 7277
96
Professional Regulatory Board of Pharmacy Resolution No. 05 series of 2021
97
I, II
98
True
99
RA 8203
100
Department of Health
Module 2 Part 1
Module 2 Part 1
ユーザ名非公開 · 100問 · 1年前Module 2 Part 1
Module 2 Part 1
100問 • 1年前Module 1
Module 1
ユーザ名非公開 · 13問 · 1年前Module 1
Module 1
13問 • 1年前Module 2
Module 2
ユーザ名非公開 · 100問 · 1年前Module 2
Module 2
100問 • 1年前Antibiotics
Antibiotics
ユーザ名非公開 · 10問 · 1年前Antibiotics
Antibiotics
10問 • 1年前Module 2 Part 2
Module 2 Part 2
ユーザ名非公開 · 100問 · 1年前Module 2 Part 2
Module 2 Part 2
100問 • 1年前Module 2 (Part 2)
Module 2 (Part 2)
ユーザ名非公開 · 100問 · 1年前Module 2 (Part 2)
Module 2 (Part 2)
100問 • 1年前Module 2 Part 3
Module 2 Part 3
ユーザ名非公開 · 85問 · 1年前Module 2 Part 3
Module 2 Part 3
85問 • 1年前Module 4
Module 4
ユーザ名非公開 · 100問 · 1年前Module 4
Module 4
100問 • 1年前Module 4 Part 2
Module 4 Part 2
ユーザ名非公開 · 100問 · 1年前Module 4 Part 2
Module 4 Part 2
100問 • 1年前Module 4 Part 3
Module 4 Part 3
ユーザ名非公開 · 60問 · 1年前Module 4 Part 3
Module 4 Part 3
60問 • 1年前Module 2 (Part 4)
Module 2 (Part 4)
ユーザ名非公開 · 68問 · 1年前Module 2 (Part 4)
Module 2 (Part 4)
68問 • 1年前Randome Questions
Randome Questions
ユーザ名非公開 · 13問 · 1年前Randome Questions
Randome Questions
13問 • 1年前1
1
ユーザ名非公開 · 100問 · 1年前1
1
100問 • 1年前Module 2 (Part 5)
Module 2 (Part 5)
ユーザ名非公開 · 100問 · 1年前Module 2 (Part 5)
Module 2 (Part 5)
100問 • 1年前2
2
ユーザ名非公開 · 100問 · 1年前2
2
100問 • 1年前Module 2 (Part 6)
Module 2 (Part 6)
ユーザ名非公開 · 68問 · 1年前Module 2 (Part 6)
Module 2 (Part 6)
68問 • 1年前Module 4 Part 1
Module 4 Part 1
ユーザ名非公開 · 5問 · 1年前Module 4 Part 1
Module 4 Part 1
5問 • 1年前BCS
BCS
ユーザ名非公開 · 36問 · 1年前BCS
BCS
36問 • 1年前Routes of Administration
Routes of Administration
ユーザ名非公開 · 79問 · 1年前Routes of Administration
Routes of Administration
79問 • 1年前Pharmacokinetics
Pharmacokinetics
ユーザ名非公開 · 86問 · 1年前Pharmacokinetics
Pharmacokinetics
86問 • 1年前Enzyme Inducers and Enzyme Inhibitors
Enzyme Inducers and Enzyme Inhibitors
ユーザ名非公開 · 25問 · 1年前Enzyme Inducers and Enzyme Inhibitors
Enzyme Inducers and Enzyme Inhibitors
25問 • 1年前Metabolism and Excretion
Metabolism and Excretion
ユーザ名非公開 · 31問 · 1年前Metabolism and Excretion
Metabolism and Excretion
31問 • 1年前PHARMACODYNAMICS
PHARMACODYNAMICS
ユーザ名非公開 · 88問 · 1年前PHARMACODYNAMICS
PHARMACODYNAMICS
88問 • 1年前Ramdom
Ramdom
ユーザ名非公開 · 6問 · 1年前Ramdom
Ramdom
6問 • 1年前A. Parasympathetic (Cholinergic) Drugs
A. Parasympathetic (Cholinergic) Drugs
ユーザ名非公開 · 43問 · 1年前A. Parasympathetic (Cholinergic) Drugs
A. Parasympathetic (Cholinergic) Drugs
43問 • 1年前3
3
ユーザ名非公開 · 100問 · 1年前3
3
100問 • 1年前4
4
ユーザ名非公開 · 100問 · 1年前4
4
100問 • 1年前Module 1
Module 1
ユーザ名非公開 · 100問 · 1年前Module 1
Module 1
100問 • 1年前Module 1
Module 1
ユーザ名非公開 · 100問 · 1年前Module 1
Module 1
100問 • 1年前Module 2
Module 2
ユーザ名非公開 · 100問 · 1年前Module 2
Module 2
100問 • 1年前Module 3
Module 3
ユーザ名非公開 · 100問 · 1年前Module 3
Module 3
100問 • 1年前Module 2
Module 2
ユーザ名非公開 · 100問 · 1年前Module 2
Module 2
100問 • 1年前Module 3
Module 3
ユーザ名非公開 · 100問 · 1年前Module 3
Module 3
100問 • 1年前Module 3 Rationales
Module 3 Rationales
ユーザ名非公開 · 100問 · 1年前Module 3 Rationales
Module 3 Rationales
100問 • 1年前Terms
Terms
ユーザ名非公開 · 19問 · 1年前Terms
Terms
19問 • 1年前Module 3 Rationales
Module 3 Rationales
ユーザ名非公開 · 29問 · 1年前Module 3 Rationales
Module 3 Rationales
29問 • 1年前Excipients
Excipients
ユーザ名非公開 · 19問 · 1年前Excipients
Excipients
19問 • 1年前Module 4
Module 4
ユーザ名非公開 · 100問 · 1年前Module 4
Module 4
100問 • 1年前Flavors,Sweeteners, and Colors
Flavors,Sweeteners, and Colors
ユーザ名非公開 · 17問 · 1年前Flavors,Sweeteners, and Colors
Flavors,Sweeteners, and Colors
17問 • 1年前Module 5
Module 5
ユーザ名非公開 · 100問 · 1年前Module 5
Module 5
100問 • 1年前Anti Glaucoma
Anti Glaucoma
ユーザ名非公開 · 23問 · 1年前Anti Glaucoma
Anti Glaucoma
23問 • 1年前B. Parasympathetic (Cholinergic) Blockers — Anti Cholinergic Agents
B. Parasympathetic (Cholinergic) Blockers — Anti Cholinergic Agents
ユーザ名非公開 · 20問 · 1年前B. Parasympathetic (Cholinergic) Blockers — Anti Cholinergic Agents
B. Parasympathetic (Cholinergic) Blockers — Anti Cholinergic Agents
20問 • 1年前C. Sympathetic (Adrenergic) Drugs
C. Sympathetic (Adrenergic) Drugs
ユーザ名非公開 · 80問 · 1年前C. Sympathetic (Adrenergic) Drugs
C. Sympathetic (Adrenergic) Drugs
80問 • 1年前D. Sympathetic (Adrenergic) BLOCKERS
D. Sympathetic (Adrenergic) BLOCKERS
ユーザ名非公開 · 15問 · 1年前D. Sympathetic (Adrenergic) BLOCKERS
D. Sympathetic (Adrenergic) BLOCKERS
15問 • 1年前E. Nicotinic Receptor Blockers
E. Nicotinic Receptor Blockers
ユーザ名非公開 · 30問 · 1年前E. Nicotinic Receptor Blockers
E. Nicotinic Receptor Blockers
30問 • 1年前F. Central Muscle Relaxants (or Spasmolytic agents)
F. Central Muscle Relaxants (or Spasmolytic agents)
ユーザ名非公開 · 19問 · 1年前F. Central Muscle Relaxants (or Spasmolytic agents)
F. Central Muscle Relaxants (or Spasmolytic agents)
19問 • 1年前Rationale Quiz 1.0
Rationale Quiz 1.0
ユーザ名非公開 · 13問 · 1年前Rationale Quiz 1.0
Rationale Quiz 1.0
13問 • 1年前A. Anxiolytic Agents
A. Anxiolytic Agents
ユーザ名非公開 · 26問 · 1年前A. Anxiolytic Agents
A. Anxiolytic Agents
26問 • 1年前B.1 Drugs for Depression
B.1 Drugs for Depression
ユーザ名非公開 · 29問 · 1年前B.1 Drugs for Depression
B.1 Drugs for Depression
29問 • 1年前B.2 Drugs for Mania / Bipolar Disorder
B.2 Drugs for Mania / Bipolar Disorder
ユーザ名非公開 · 15問 · 1年前B.2 Drugs for Mania / Bipolar Disorder
B.2 Drugs for Mania / Bipolar Disorder
15問 • 1年前C. Drugs for Psychoses - Typical and Atypical Antipsychotics
C. Drugs for Psychoses - Typical and Atypical Antipsychotics
ユーザ名非公開 · 44問 · 1年前C. Drugs for Psychoses - Typical and Atypical Antipsychotics
C. Drugs for Psychoses - Typical and Atypical Antipsychotics
44問 • 1年前D. Drugs for Seizure Disorders
D. Drugs for Seizure Disorders
ユーザ名非公開 · 36問 · 1年前D. Drugs for Seizure Disorders
D. Drugs for Seizure Disorders
36問 • 1年前E. General Anesthetics
E. General Anesthetics
ユーザ名非公開 · 32問 · 1年前E. General Anesthetics
E. General Anesthetics
32問 • 1年前G. Anti-Parkinson Drugs
G. Anti-Parkinson Drugs
ユーザ名非公開 · 26問 · 1年前G. Anti-Parkinson Drugs
G. Anti-Parkinson Drugs
26問 • 1年前H. Drugs for Alzheimer's Disease
H. Drugs for Alzheimer's Disease
ユーザ名非公開 · 6問 · 1年前H. Drugs for Alzheimer's Disease
H. Drugs for Alzheimer's Disease
6問 • 1年前Rationale Quiz 2
Rationale Quiz 2
ユーザ名非公開 · 5問 · 1年前Rationale Quiz 2
Rationale Quiz 2
5問 • 1年前1
1
ユーザ名非公開 · 100問 · 1年前1
1
100問 • 1年前2
2
ユーザ名非公開 · 100問 · 1年前2
2
100問 • 1年前3
3
ユーザ名非公開 · 100問 · 1年前3
3
100問 • 1年前4
4
ユーザ名非公開 · 100問 · 1年前4
4
100問 • 1年前6
6
ユーザ名非公開 · 100問 · 1年前6
6
100問 • 1年前1. Diuretics
1. Diuretics
ユーザ名非公開 · 34問 · 1年前1. Diuretics
1. Diuretics
34問 • 1年前2. Angiotensin Blockers
2. Angiotensin Blockers
ユーザ名非公開 · 12問 · 1年前2. Angiotensin Blockers
2. Angiotensin Blockers
12問 • 1年前3 and 4. CCBs: Non-dihydropyridines and Vasodilators
3 and 4. CCBs: Non-dihydropyridines and Vasodilators
ユーザ名非公開 · 20問 · 1年前3 and 4. CCBs: Non-dihydropyridines and Vasodilators
3 and 4. CCBs: Non-dihydropyridines and Vasodilators
20問 • 1年前Module 2
Module 2
ユーザ名非公開 · 17問 · 1年前Module 2
Module 2
17問 • 1年前Pharmacodynamics
Pharmacodynamics
ユーザ名非公開 · 23問 · 1年前Pharmacodynamics
Pharmacodynamics
23問 • 1年前Drug Classes
Drug Classes
ユーザ名非公開 · 15問 · 1年前Drug Classes
Drug Classes
15問 • 1年前MOA
MOA
ユーザ名非公開 · 24問 · 1年前MOA
MOA
24問 • 1年前5. Sympatholytics
5. Sympatholytics
ユーザ名非公開 · 11問 · 1年前5. Sympatholytics
5. Sympatholytics
11問 • 1年前B. Drugs for Heart Failure
B. Drugs for Heart Failure
ユーザ名非公開 · 6問 · 1年前B. Drugs for Heart Failure
B. Drugs for Heart Failure
6問 • 1年前C. Drugs for Arrhythmia
C. Drugs for Arrhythmia
ユーザ名非公開 · 36問 · 1年前C. Drugs for Arrhythmia
C. Drugs for Arrhythmia
36問 • 1年前D. Drugs for Hyperlipidemia
D. Drugs for Hyperlipidemia
ユーザ名非公開 · 11問 · 1年前D. Drugs for Hyperlipidemia
D. Drugs for Hyperlipidemia
11問 • 1年前E. Angina Pectoris
E. Angina Pectoris
ユーザ名非公開 · 10問 · 1年前E. Angina Pectoris
E. Angina Pectoris
10問 • 1年前F. Thrombotic Disorders
F. Thrombotic Disorders
ユーザ名非公開 · 50問 · 1年前F. Thrombotic Disorders
F. Thrombotic Disorders
50問 • 1年前Antidotes
Antidotes
ユーザ名非公開 · 8問 · 1年前Antidotes
Antidotes
8問 • 1年前Deficiencies
Deficiencies
ユーザ名非公開 · 9問 · 1年前Deficiencies
Deficiencies
9問 • 1年前A. Growth Hormones
A. Growth Hormones
ユーザ名非公開 · 16問 · 1年前A. Growth Hormones
A. Growth Hormones
16問 • 1年前B. Adrenal Steroids
B. Adrenal Steroids
ユーザ名非公開 · 30問 · 1年前B. Adrenal Steroids
B. Adrenal Steroids
30問 • 1年前C. GnRH, FSH & LH & Sex Hormones
C. GnRH, FSH & LH & Sex Hormones
ユーザ名非公開 · 45問 · 1年前C. GnRH, FSH & LH & Sex Hormones
C. GnRH, FSH & LH & Sex Hormones
45問 • 1年前D. Thyroid Hormones
D. Thyroid Hormones
ユーザ名非公開 · 15問 · 1年前D. Thyroid Hormones
D. Thyroid Hormones
15問 • 1年前E. Diabetes Mellitus
E. Diabetes Mellitus
ユーザ名非公開 · 70問 · 1年前E. Diabetes Mellitus
E. Diabetes Mellitus
70問 • 1年前F. Drugs for osteoporosis
F. Drugs for osteoporosis
ユーザ名非公開 · 21問 · 1年前F. Drugs for osteoporosis
F. Drugs for osteoporosis
21問 • 1年前Rationale Quiz
Rationale Quiz
ユーザ名非公開 · 10問 · 1年前Rationale Quiz
Rationale Quiz
10問 • 1年前A. Asthma
A. Asthma
ユーザ名非公開 · 34問 · 1年前A. Asthma
A. Asthma
34問 • 1年前B. Allergic Rhinitis
B. Allergic Rhinitis
ユーザ名非公開 · 27問 · 1年前B. Allergic Rhinitis
B. Allergic Rhinitis
27問 • 1年前問題一覧
1
Active Ingredient, Diluent or Filler, Binder, Disintegrant, Lubricant
2
Oral Solution
3
Oral pharmaceutical solutions are usually formulated so that the patient receives the usual dose in a conveniently administered volume, such as 5 mL (1 tsp), 10 mL, or 15 mL (1 tbsp).
4
Enhances crystal growth formation
5
Suspended particles settle rapidly
6
Formation of a compact when the particles eventually settle
7
Suspensions are chemically more stable than solutions.
8
Add an amount of flocculating agent that will bring about a sedimentation volume equal to 1
9
Human insulin
10
Gelatin coated tablet
11
Class III
12
Sun protection factor
13
Betaine
14
Tablet Binder
15
Adsorbent
16
Humectant
17
Emulsion and suspension
18
Castor Oil
19
Yellow wax, yellow petrolatum
20
I, III
21
I, II, IV
22
6.21 mL
23
Liniments – Oleaginous
24
I, II, III
25
Purified Water
26
Remains stable in rectal fluids
27
It is a naturally occurring alkaloid.
28
Lip Balms, Mouthwashes, Antiperspirants, Diaper Ointments
29
Strong Antimicrobial
30
HMW alcohols
31
Tumbling
32
Reversible protein precipitation
33
Gas Sterilization
34
Nitroso-Dyes
35
Decrease dissolution leading to a less violent effervescence.
36
Chipping
37
I, II and III
38
Magaldrate
39
II-V-III-I-IV
40
Coat the capsules with polyvinyl acetate phthalate.
41
Aging
42
100 – 120 mEq
43
Granules will be hard
44
Antioxidant
45
Type II
46
Brownian motion
47
225 g
48
Chewable tablet
49
Refractive index
50
Physiological
51
Ion-Dipole, Ion- Induced Dipole Forces
52
5- to 6-membered rings
53
Gibbs Free Energy
54
Metal Complexes, Organic Complexes, Inclusion/Occlusion Compounds
55
Hexadentate
56
∆ E = EB + EA
57
3rd Law of Thermodynamics
58
I, II, III
59
I, II, III
60
I, III, IV
61
I, II, III
62
Cup and Bob, Cone and Plate
63
Tobramycin, Chloramphenicol Palmitate Suspension
64
Electrokinetic Potential
65
0.76 g
66
0.5
67
Hydrogen bond
68
Micelles are aggregates of molecules or ions of the substance dissolved in the dispersion medium.
69
Light Scattering
70
The configuration of a solid molecule has NO effect on its solubility.
71
The solubility of a solid in an ideal solution depends on the temperature, melting point of the solid and molar heat of fusion.
72
Gelatin
73
Work Of Adhesion
74
AOTA
75
both Nernst Potential and Electrothermodynamic Potential
76
The velocity of the particles decreases with decreasing particle size
77
Spherocolloids form dispersions of relatively high viscosity
78
9%
79
18 mL
80
– 1.6 dynes/cm
81
NOTA
82
When the ligand provides one group for attachment to the central ion, the chelate is called bidentate
83
NOTA
84
NOTA
85
NOTA
86
50%
87
1.9
88
Dispensing the remaining balance of medicines ordered in the prescription
89
Only the brand name is written on the prescription, with the phrase, “No substitution”
90
PDEA
91
Philippine Pharmacy Act
92
Primary care, medicines, diagnostic and laboratory tests, preventive, curative, rehabilitative services
93
S-1
94
NOTA
95
RA 7277
96
Professional Regulatory Board of Pharmacy Resolution No. 05 series of 2021
97
I, II
98
True
99
RA 8203
100
Department of Health